Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.34 |
| ▸ | CTSS | P25774 | 5/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 4/20 | 0.31 |
| ▸ | CTSB | P07858 | 3/20 | 0.31 |
| ▸ | CTSH | P09668 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12504722 | 0.86 | CPB2 (0.33) | CTSKCTSSCPB2CTSLCTSB | |
| SCHEMBL14943231 | 0.80 | CTSK (0.35) | CTSKCTSSCPB2CTSLCTSB | |
| SCHEMBL16328153 | 0.80 | CTSK (0.35) | CTSKCTSSCPB2CTSLCTSB | |
| SCHEMBL14943710 | 0.76 | SMN1; SMN2 (0.37) | CTSKCTSSCPB2CTSLCTSB | |
| SCHEMBL15219928 | 0.75 | CTSK (0.34) | CTSKCTSSCTSL | |
| SCHEMBL14943769 | 0.75 | CTSK (0.34) | CTSKCTSSCTSL | |
| SCHEMBL15219659 | 0.74 | CTSK (0.35) | CTSKCTSSCTSLCTSB | |
| SCHEMBL16328154 | 0.74 | CTSK (0.35) | CTSKCTSSCTSLCTSB | |
| SCHEMBL8227114 | 0.73 | CTSK (0.38) | CTSKCTSSCPB2CTSLCTSB | |
| SCHEMBL14943767 | 0.73 | CTSK (0.36) | CTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575208-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-20100272681-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272681-A1 | Inhibitors of Serine Proteases | SERPINB1, PRSS1, SPINT2 | CTSK 109/4885CTSS 31/4885CPB2 95/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | CTSK 240/4885CTSS 77/4885CPB2 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.